Filter Results
Filter Results
Integrated Biologics (18) Specialized Modalities (13) Advanced Synthesis (11) Capsules & Health Ingredients (9) Corporate (3)
Media Advisory (54) New Technologies (12) Partnerships (9) Sustainability (3) New Products (2) General (1)
2025 (7) 2024 (21) 2023 (16) 2022 (10)
English (45)
Media AdvisoryX
Reset Filters
   Loading...
Showing 41‐54 of 54
Media Advisory
30 Jan 2023
Lonza Expands Manufacturing Collaboration With Asher Biotherapeutics to Include AB248, a Cis-Targeted IL-2 Immunotherapy
Asher Bio’s lead drug candidate AB248, a cis-targeted IL-2 immunotherapy for the treatment of cancer, to be manufactured at Lonza’s site in Visp (CH) Agreement builds upon...
Media Advisory
17 Jan 2023
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox Collaborations further the development of an...
Media Advisory
16 Jan 2023
Lonza Completes Expansion to Solid Form Services Facility at Bend (US) Site
The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules New facility is based at Lonza’s Bend,...
Media Advisory
09 Jan 2023
Lonza and Context Therapeutics Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being...
Media Advisory
06 Dec 2022
Fraunhofer IZI Selects Lonza’s MODA-ES® Solution to Digitalize Manufacturing Operations
The Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI) has chosen Lonza’s MODA-ES® Manufacturing Execution System (MES) to streamline its manufacturing operations
Media Advisory
31 Oct 2022
Lonza and Singzyme Announce Collaboration Agreement to Accelerate the Development of Bioconjugates
Collaboration Agreement to expand Lonza’s bioconjugation toolbox to include Singzyme’s site-selective conjugation technology
Media Advisory
25 Oct 2022
Lonza Expands Global Process Development Team and Laboratory Spaces for Cell and Gene Development
Lonza to almost double the size of the Cell and Gene Therapy Development laboratories at its Houston facility, adding an extra 15,000 square feet of laboratory space
Media Advisory
24 Oct 2022
Lonza joins GENEGUT Project to Develop a Capsule Delivery Solution for an Innovative Crohn's Disease Treatment
Four-year project aims to develop an innovative Crohn's disease treatment based on RNA and targeted delivery
Media Advisory
29 Sep 2022
Lonza Collaborates with AbTis to Extend Bioconjugation Capabilities
Collaboration to implement AbTis’ AbClick® platform into Lonza’s bioconjugation toolbox
Media Advisory
22 Aug 2022
Lonza Strengthens Micronization Portfolio with the Introduction of X-Ray Powder Diffraction Capability in Monteggio (CH)
Lonza introduces X-ray powder diffraction at its Monteggio (CH) site
Media Advisory
02 Aug 2022
The New Nebula® Multimode Reader from Lonza Streamlines Quantitative Endotoxin Detection
The Nebula® Multimode Microplate Reader has been developed and optimized for use with Lonza’s quantitative endotoxin assays
Media Advisory
09 May 2022
Lonza Acquired a new claim supporting “Food With Function Claims” in Japan for UC-II® Undenatured Type II Collagen
The new claim supports the daily knee movements of middle-aged and elderly people, such as climbing stairs, standing up, and squatting.
Media Advisory
04 May 2022
New clinical study shows Lonza’s UC-II® undenatured type II collagen helps joints feel 10 years younger
Lonza Capsules & Health Ingredients’ latest clinical research adds to 20+ years of science proving UC-II® undenatured type II collagen supports joint health at every age
Media Advisory
17 Feb 2022
Lonza extends availability of TWK10® sports probiotic to Europe
TWK10® sports probiotic, brought to market by Lonza, is an innovative form of the probiotic strain L. plantarum, and is the first probiotic strain that has been clinically studied to show an increase in exercise endurance up to 75%
< 1 2 3